Omega-3s are effective as augmentation of mood stabilizers in bipolar depression, and in some cases, they improve negative symptoms in early schizophrenia. The research is vast, but we narrow down when and how to use omega-3s in real-world practice.

Randomized controlled trials have not been kind to commercial pharmacogenetic panels, but will Genecept’s fate be any different?

Medications don’t have a good track record in PTSD, particularly in combat related trauma. Here we review two controlled trials where an old standby (mirtazapine) and a hopeful contender (riluzole) come up short.

This first-of-its-kind study looked at lightbox in PTSD with a randomized, placebo-controlled design.

There are many mood stabilizers to choose from, but which ones are the best tolerated? This meta-analysis looks at how they stack up in terms of weight gain, sedation, and overall discontinuation.

Carbamazepine or valproic acid? Both have been used to augment lithium for decades, but which one works best? A new trial tests them head-to-head.

Small studies have shown promise for treating cocaine use disorder with combination amphetamine salts/topiramate. In this larger trial, the combination was tested against a placebo.

Previous trials of baclofen for alcohol use disorder have used fixed or rather low doses, and the results have been mixed. This was the first randomized trial to allow up-titration of the dose depending on the patient’s response.

Which patients with alcohol use disorder might benefit from gabapentin most? This randomized controlled trial focused on gabapentin’s impact on alcohol use among patients with alcohol use disorder and who had also had alcohol withdrawal symptoms in the past.